Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Laekna Inc.
Industry Sector: HealthTechnology
CEO: Xiang Yang Lu, PhD
Number Of Employees: 89
Enterprise Value: $805,138,616
PE Ratio: -14.79
Exchange/Ticker 1: HKEX:2105
Exchange/Ticker 2: N/A
Latest Market Cap: $638,467,659
BioCentury | Dec 7, 2024
Finance
Revolution, Janux prep for next steps with follow-on cash
In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial
BioCentury | Sep 27, 2023
Deals
Insilico’s evolving AI deals: from ‘death by pilot’ to $80M up front
The AI company’s Exelixis partnership highlights its strategic pivots in a shifting landscape
BioCentury | Jun 29, 2023
Product Development
June 29 Quick Takes: Disclosure of impropriety jeopardizes integrity of BioXcel’s trial
Plus: Laekna completes $101M Hong Kong IPO, FDA again rebuffs Alvotech’s Humira biosimilar and updates from Vesalius, Alkermes and Vertex Ventures
BioCentury | May 19, 2022
Product Development
May 18 Quick Takes: Enanta tumbles after hours after missing RSV endpoint
Plus: House E&C passes user fee bill and updates from Hengrui, Laekna, Prenetics, Enanta and more
BioCentury | Mar 29, 2022
Management Tracks
Rangwala to be CMO at Karyopharm
Plus Jones becomes CFO at Sense, and updates from Enzo, Dice and more
BioCentury | Jun 29, 2019
Finance
New fund to expand Anlong’s tool kit for early stage deals
With a new U.S. dollar fund Anlong aims to fund Chinese companies looking to list in Hong Kong or overseas
BioCentury | Sep 14, 2018
Emerging Company Profile
Laekna’s jumping off place
Why Laekna Therapeutics opted to start with a trio of Novartis compounds
Items per page:
1 - 10 of 10